Merck announced that the U.S. Food & Drug Administration approved its once‑daily, oral combination regimen of doravirine and islatravir for adults with virologically suppressed HIV‑1 infection on April 21, 2026, marking the company’s first entry into the oral HIV treatment market.
The new regimen is the first FDA‑approved two‑drug HIV therapy that does not include an integrase inhibitor yet demonstrates non‑inferior efficacy, offering patients a convenient once‑daily option that could improve adherence and broaden treatment choices.
Merck’s existing HIV portfolio already includes doravirine as Pifeltro and Delstrigo; the approval expands the portfolio and is expected to open a new revenue stream for the pharmaceutical segment, reinforcing the company’s long‑standing commitment to HIV research over 35 years.
The approval follows Merck’s collaboration with Gilead Sciences on long‑acting combinations involving islatravir and lenacapavir, and reflects the company’s ability to overcome past safety concerns with islatravir.
The global HIV market remains large, with 40.8 million people living with HIV and 1.3 million new infections annually, indicating a sizable addressable market for the new regimen.
The approval enhances Merck’s competitive position against major players such as Gilead Sciences and ViiV Healthcare, potentially capturing market share in the oral HIV treatment segment.
This milestone also signals progress in Merck’s HIV pipeline, which includes other investigational agents for treatment and prevention.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.